Skip to main content

Table 1 Baseline Characteristics of Participants With and Without Heart Failure

From: Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone

  Hospitalized and Fatal HF Treated, Nonhospitalized HF Without HF*
  C D C D C D
No. of subjects 327 346 93 145 14493 8347
Age, years, mean (SD) 70.7 (8.3) 71.0 (8.6) 70.3 (8.2) 69.9 (7.2) 66.8 (7.6) 66.6 (7.6)
Race       
   White, non-Hispanic, % 61.2 55.8 63.4 64.8 47.3 46.3
   Black, non-Hispanic, % 30.6 35.3 32.3 30.3 32.0 32.9
   Hispanic, % 4.6 5.5 2.2 2.8 15.6 16.1
   Other, % 3.7 3.1 2.2 2.1 5.1 4.8
Women, % 42.8 39.6 33.3 44.1 47.0 46.5
Education, years, mean (SD) 10.5 (3.9) 10.7 (3.4) 11.3 (3.6) 12.1 (3.2) 11.0 (4.0) 11.0 (4.0)
Cigarette smoking, current, % 19.0 19.4 11.8 17.9 22.1 21.9
Antihypertensive treatment       
   Treated > 2 months, % 86.9 86.8 95.7 95.2 86.9 86.7
   Treated < 2 months, % 3.3 3.3 1.1 0.0 3.3 3.3
   Untreated, % 9.8 10.0 3.2 4.8 9.9 10.0
Blood pressure, mm Hg, mean (SD) 147.8/81.1 (17.6/10.9) 150.1/81.8 (16.5/11.0) 147.1/82.2 (16.0/10.5) 145.9/82.0 (15.8/10.6) 146.2/84.1 (15.6/10.0) 146.1/84.1 (15.7/10)
Pulse pressure, mm Hg, mean (SD) 66.7 (16.5) 68.3 (15.3) 64.9 (13.0) 63.9 (15.3) 62.1 (14.1) 62.1 (14.2)
Eligibility risk factors       
   LVH       
By electrocardiogram, % 20.5 22.3 18.3 21.4 16.1 16.1
By echocardiogram, % 6.3 4.7 4.4 1.4 4.6 4.6
   Old MI or stroke, % 36.1 34.7 41.9 33.1 23.1 22.3
   CABG/Angioplasty, % 22.6 18.5 25.8 26.2 12.9 12.6
   ASCVD, % 33.3 29.2 31.2 31.0 23.4 24.6
   Type 2 diabetes, % 46.8 48.3 43.0 40.7 35.9 34.7
   HDL<35 mg/dl, % 12.8 13.6 14.0 13.8 11.9 11.7
   ST-T wave changes, % 12.8 10.6 10.9 12.9 10.4 10.2
  1. HF= Heart Failure C = Chlorthalidone treatment group D = Doxazosin treatment group mm Hg = millimeters mercury LVH = Left ventricular hypertrophy MI = Myocardial infarction CABG = Coronary artery bypass graft ASCVD = Atherosclerotic cardiovascular disease HDL = High-density lipoprotein *Only participants with at least one follow-up visit are included. 355 chlorthalidone and 229 doxazosin participants are excluded due to lack of at least one follow-up visit. For trial eligibility, participants had to have at least 1 other risk factor in addition to hypertension. The indicated risk factors are not mutually exclusive or exhaustive and do not represent prevalence. P = .0484